Yes, aspirin is appropriate and recommended as long-term maintenance therapy for secondary prevention after an ischemic cerebrovascular accident (stroke).
For patients with noncardioembolic ischemic stroke, antiplatelet therapy with aspirin 50-325 mg daily is indicated for long-term secondary prevention to reduce the risk of recurrent ischemic stroke and other cardiovascular events 1.
Treatment Algorithm
Initial Phase (First 21-90 Days)
- For minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4): Start dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel within 12-24 hours, continue for 21-90 days 1
- For other noncardioembolic strokes: Start single antiplatelet therapy (SAPT) immediately
Long-Term Maintenance (After 90 Days)
Switch to single antiplatelet therapy with one of the following options 1:
- Aspirin 50-325 mg daily (most commonly used, cost-effective)
- Clopidogrel 75 mg daily
- Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily
Key Evidence Supporting Aspirin
The 2021 AHA/ASA guidelines provide Class 1, Level A recommendations for aspirin in secondary stroke prevention 1. Aspirin monotherapy is preferred over anticoagulation for noncardioembolic stroke, as anticoagulation increases bleeding risk without additional benefit 1.
Aspirin reduces recurrent stroke risk by approximately 13 events per 1000 patients treated 2, with a number needed to treat of 79 to prevent one death or dependency 2.
Critical Warnings About Long-Term DAPT
Do NOT continue dual antiplatelet therapy (aspirin + clopidogrel) beyond 90 days 1. Long-term DAPT:
- Does not reduce recurrent stroke risk (OR 0.92, not significant) 3
- Significantly increases hemorrhagic stroke risk (RR 1.67) 3
- Increases major bleeding events (RR 1.90) 1, 3
The risk of intracranial hemorrhage with prolonged DAPT outweighs any potential benefit, particularly in older patients and those with more severe strokes 1.
Dosing Considerations
While the guideline recommends 50-325 mg daily, most clinicians use 75-100 mg daily for long-term maintenance 1. Recent evidence suggests weight-based dosing may be more effective (75-100 mg for patients <70 kg, higher doses for >70 kg), though this is primarily from primary prevention studies 1.
When NOT to Use Aspirin
Switch to anticoagulation instead of aspirin if:
- Cardioembolic stroke (especially atrial fibrillation) is identified 1
- The stroke is determined to be cardioembolic in origin
Monitoring and Safety
The risk of hemorrhagic stroke with aspirin in secondary prevention is approximately 0.2 events per 1000 patient-years 4—a small risk that is significantly outweighed by the cardiovascular benefits 4.
Common pitfalls to avoid:
- Continuing DAPT indefinitely beyond 90 days without a separate indication (e.g., recent cardiac stent)
- Using triple antiplatelet therapy (associated with excess bleeding without benefit) 1
- Switching or adding antiplatelet agents without clear evidence of benefit 1
If Patient Has Recurrent Stroke on Aspirin
The evidence for switching antiplatelet agents is weak 1. If a patient on aspirin has another stroke:
- First, ensure the stroke is truly noncardioembolic (rule out atrial fibrillation, other cardioembolic sources)
- Consider switching to clopidogrel or aspirin-dipyridamole combination
- The effectiveness of simply increasing aspirin dose is not well established 1
The bottom line: Aspirin remains a cornerstone of long-term secondary stroke prevention for noncardioembolic ischemic stroke, with proven efficacy and an acceptable safety profile when used as monotherapy after the initial 21-90 day period 1, 5, 6.